Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia

American Journal of Cardiovascular Drugs

Volumn 11, Issue 6, 2011, Pages 363-370

  Lee, Wai Ping ^a   Datta, Borunendra N ^a   Ong, Beng Beng ^a   Rees, Alan ^a   Halcox, Julian ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

apheresis; cholesterol; Hypercholesterolaemia; LDL; lipoprotein

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B; BRADYKININ; DEXTRAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

APHERESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; DEXTRAN SULFATE ADSORPTION; DIAGNOSTIC PROCEDURE; DIZZINESS; DRUG APPROVAL; FAMILIAL HYPERCHOLESTEROLEMIA; FILTRATION PLASMAPHERESIS; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEALTH CARE COST; HEMOPERFUSION; HEPARIN EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION; HOMOZYGOSITY; HUMAN; HYPOTENSION; IMMUNOADSORPTION; INFORMATION RETRIEVAL; LIPOPROTEIN APHERESIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMAPHERESIS; POLYACRYLATE FULL BLOOD ADSORPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY; TREATMENT INDICATION; VOMITING;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); PLASMAPHERESIS;

EID: 83055178362     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11594970-000000000-00000     Document Type: Review

References (50)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17; 106 (25): 3143-421
2. DeMott K, Nherera L, Shaw EJ, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: The identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008
3. Mabuchi H, Michishita I, Takeda M, et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987 Nov; 68 (1-2): 19-25 (Pubitemid 17151101)
4. Witztum JL, Simmons D, Steinberg D, et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 1989; 79: 16-28 (Pubitemid 19043670)
5. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts: Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974; 249: 5153-62
6. Rader D, Hobbs H. Disorders of lipoprotein metabolism. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical, 2008: 2416-29
7. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003 May; 168 (1): 1-14 (Pubitemid 36559596)
8. van Aalst-Cohen ES, Jansen AC, Tanck MW, et al. Diagnosing familial hypercholesterolaemia: The relevance of genetic testing. Eur Heart J 2006 Sep; 7 (18): 2240-6 (Pubitemid 44412840)
9. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993 Jul 15; 72 (2): 171-6 (Pubitemid 23205873)
10. Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: A single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis 1992 Oct; 96 (2-3): 91-107
11. Humphries SE, Whittall RA, Hubbart CS, et al., on behalf of Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: Relation to plasma lipid levels and coronary heart disease risk. JMed Genet 2006 Dec; 43 (12): 943-9 (Pubitemid 46080192)
12. Graham CA, McIlhatton BP, Kirk CW, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005 Oct; 182 (2): 331-40 (Pubitemid 41267202)
13. Heath KE, Humphries SE, Middleton-Price H, et al. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001 Apr; 9 (4): 244-52 (Pubitemid 32366691)
14. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975 May 31; 1 (7918): 1208-11
15. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1976 Jun 12; 1 (7972): 1261-5
16. Yokoyama S, Hayashi R, Satani M, et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985 Nov-Dec; 5 (6): 613-22 (Pubitemid 16170855)
17. Bosch T, Schmidt B, Blumenstein M, et al. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993 Jul; 17 (7): 640-52 (Pubitemid 23278009)
18. Eisenhauer T, Armstrong VW, Wieland H, et al. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 1987 Feb 16; 65 (4): 161-8 (Pubitemid 17023461)
19. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008 Jun; 198 (2): 247-55
20. Moriarty PM. Low-density lipoprotein apheresis. In: Ballantyne CM, editor. Clinical lipidology: A companion to Braunwald's heart disease. Philadelphia (PA): Saunders Elsevier, 2009: 363-72
21. Otto C, Kern P, Bambauer R, et al. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003 Dec; 27 (12): 1116-22 (Pubitemid 38037567)
22. Klingel R, Mausfeld P, Fassbender C, et al. Lipid filtration: safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004 Jun; 30 (3): 245-54 (Pubitemid 38698339)
23. Richter WO, Jacob BG, Ritter MM, et al. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993 Jul; 42 (7): 888-94 (Pubitemid 23207119)
24. Nakajima T, Nakamura T, Funahashi T, et al. A novel system of LDL apheresis combining a centrifugal plasma separator with a specific LDL adsorption column. Atherosclerosis 1988 Oct; 73 (2-3): 143-8
25. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006 Nov; 189 (1): 31-8 (Pubitemid 44444914)
26. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010 Feb; 208 (2): 317-21
27. Thompson GR. LDL apheresis. Atherosclerosis 2003 Mar; 167 (1): 1-13 (Pubitemid 36258395)
28. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010 Dec; 21 (6): 487-91
29. Kroon AA, Aengevaeren WR, van der Werf T, et al., LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996 May 15; 93 (10): 1826-35 (Pubitemid 26154034)
30. Palcoux JB, Atassi-Dumont M, Lefevre P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008 Jun; 12 (3): 195-201 (Pubitemid 351743600)
31. Hudgins LC, Kleinman B, Scheuer A, et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008 Nov 1; 102 (9): 1199-204
32. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008 Dec 1; 102 (11): 1438-43
33. Koziolek MJ,Hennig U, Zapf A, et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Apher Dial 2010 Apr; 14 (2): 143-52
34. Parhofer KG, Barrett PH, Demant T, et al. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J Lipid Res 2000 Oct; 41 (10): 1596-603
35. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997 Oct; 38 (10): 2071-8 (Pubitemid 27468015)
36. Jaeger BR, Richter Y, Nagel D, et al., on behalf of Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009 Mar; 6 (3): 229-39
37. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein( a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009 Jul 22; 302 (4): 412-23
38. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease metaanalysis of prospective studies. Circulation 2000 Sep 5; 102 (10): 1082-5
39. Clarke R, Peden JF, Hopewell JC, et al., on behalf of the PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 Dec 24; 361 (26): 2518-28
40. Schuff-Werner P, Schütz E, Seyde WC, et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989 Feb; 19 (1): 30-7 (Pubitemid 19093382)
41. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium- dependent vasodilatation in hypercholesterolemic humans. Circulation 1997 Jan 7; 95 (1): 76-82 (Pubitemid 27029946)
42. Yavasoglu I, Kadikoylu G, Akyol A, et al. Therapeutic apheresis: Results from a single center in Turkey. Transfus Apher Sci 2007 Jun; 36 (3): 249-53 (Pubitemid 47096815)
43. BoschT, Schmidt B,KleophasW, et al.LDLhemoperfusion: A newprocedure for LDL apheresis. Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 1997 Oct; 21 (10): 1060-5 (Pubitemid 27444690)
44. Sachais BS,Katz J, Ross J, et al. Long-term effects ofLDL apheresis in patients with severe hypercholesterolemia. J Clin Apher 2005 Dec; 20 (4): 252-5
45. Olbricht CJ, Schamann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibition. Lancet 1992; 340: 908-9
46. University of Michigan Health System. LDL apheresis: Treating familial ypercholesterolemia with LDL apheresis [online]. Available from URL: http:// www.med.umich.edu/cvc/services/site-lipid/ldl.html [Accessed 2011 Jul 1]
47. Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73 (4): 259-64 (Pubitemid 44448887)
48. Muso E, Mune M, Fujii Y, et al., on behalf of the Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int Suppl. 1999 Jul; 71: S122-5 (Pubitemid 29304830)
49. Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997 Mar; 16 (3): 290-7 (Pubitemid 27138293)
50. Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of lowdensity lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996 Dec 15; 125 (12): 945-54 (Pubitemid 26424522)